Eva Marie Lonn

Q: What Schools Are Affiliated With Eva Marie Lonn

Eva Marie Lonn is affiliated with the following schools: McGill University, McMaster University, Dalhousie University

Eva Marie Lonn's AcademicInfluence.com Rankings

Eva Marie Lonn

Medical

#3202

World Rank

#3658

Historical Rank

Cardiology

#330

World Rank

#341

Historical Rank

Public Health

#504

World Rank

#521

Historical Rank

Epidemiology

#608

World Rank

#633

Historical Rank

medical Degrees

Eva Marie Lonn

Philosophy

#9195

World Rank

#12717

Historical Rank

Logic

#6184

World Rank

#7673

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Eva Marie Lonn's Degrees

Doctorate Medicine Stanford University

Why Is Eva Marie Lonn Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Eva Marie Lonn's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. (2008) (2103)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (2017) (1499)
Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. (2006) (1484)
Homocysteine lowering with folic acid and B vitamins in vascular disease. (2006) (1166)
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. (2005) (1119)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (2018) (993)
Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence (1999) (909)
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. (2009) (789)
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. (2013) (756)
Effects of Ramipril and Vitamin E on Atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) (2001) (734)
2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. (2016) (734)
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. (2016) (621)
Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. (2012) (545)
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. (1994) (502)
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. (2016) (499)
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. (2010) (477)
Darapladib for preventing ischemic events in stable coronary heart disease. (2014) (475)
Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril (2001) (465)
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial (2017) (464)
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial (2017) (464)
Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. (2005) (443)
Use of ramipril in preventing stroke: double blind randomised trial (2002) (427)
The Antioxidant Vitamins and Cardiovascular Disease: A Critical Review of Epidemiologic and Clinical Trial Data (1995) (425)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. (2002) (365)
Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE). (2000) (334)
Microvascular Function Predicts Cardiovascular Events in Primary Prevention: Long-Term Results From the Firefighters and Their Endothelium (FATE) Study (2011) (329)
Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals (2013) (301)
Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. (2007) (300)
Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease (2003) (281)
Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study (2006) (271)
The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. (2001) (267)
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis (2005) (262)
Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. (2019) (249)
Homocysteine-Lowering Therapy and Stroke Risk, Severity, and Disability: Additional Findings From the HOPE 2 Trial (2009) (248)
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study (2003) (241)
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials (2017) (228)
C-Reactive Protein as a Screening Test for Cardiovascular Risk in a Multiethnic Population (2004) (201)
Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study (2019) (191)
Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose (2008) (185)
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. (2016) (185)
Effects of Ramipril on Coronary Events in High-Risk Persons: Results of the Heart Outcomes Prevention Evaluation Study (2001) (184)
Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. (2003) (174)
Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals12345 (2014) (173)
The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. (2010) (168)
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. (2011) (161)
The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. (1996) (155)
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. (2021) (148)
Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. (2005) (146)
Multiple Infections and Subsequent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study (2003) (140)
Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. (2003) (135)
Pathophysiologic and Therapeutic Importance of Tissue ACE: A Consensus Report (2002) (134)
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. (2017) (133)
Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND (2010) (133)
AIDS Research and Therapy (1996) (127)
Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. (2017) (122)
The T-786→C Mutation in Endothelial Nitric Oxide Synthase Is Associated With Hypertension (2002) (117)
The Relationship Between Trimethylamine-N-Oxide and Prevalent Cardiovascular Disease in a Multiethnic Population Living in Canada. (2015) (116)
BNP and NT‐proBNP predict echocardiographic severity of diastolic dysfunction (2008) (114)
Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes: Results of the HOPE Study Extension (2005) (113)
Race/Ethnic Differences in the Associations of the Framingham Risk Factors with Carotid IMT and Cardiovascular Events (2015) (112)
Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus (2014) (110)
Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. (2004) (109)
Epicardial fat thickness and coronary artery disease correlate independently of obesity. (2011) (109)
Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. (2008) (104)
Homocysteine-Lowering Therapy and Risk for Venous Thromboembolism (2007) (103)
In vitro high resolution intravascular imaging in muscular and elastic arteries. (1992) (101)
Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. (2004) (98)
The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. (2004) (95)
Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. (2007) (93)
Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. (2007) (91)
Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials. (2017) (90)
Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. (1993) (90)
Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease (2016) (88)
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. (2003) (84)
Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. (2011) (84)
Physical activity in patients with stable coronary heart disease: an international perspective (2013) (81)
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk (2020) (81)
Echocardiographically guided pericardiocentesis - the gold standard for the management of pericardial effusion and cardiac tamponade. (1999) (80)
Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. (2003) (80)
Cardiovascular risk in patients with mild renal insufficiency. (2003) (79)
Interrelation of saturated fat, trans fat, alcohol intake, and subclinical atherosclerosis. (2008) (79)
Pantoprazole to Prevents Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-blind, Placebo-controlled Trial. (2019) (79)
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials (2018) (78)
Cross-sectional evaluation of brachial artery flow-mediated vasodilation and C-reactive protein in healthy individuals. (2004) (77)
Abnormalities in intramyocardial arteries detected in cardiac transplant biopsy specimens and lack of correlation with abnormal intracoronary ultrasound or endothelial dysfunction in large epicardial coronary arteries. (1995) (77)
Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk (2015) (74)
Comparison of new measures of vascular function to flow mediated dilatation as a measure of cardiovascular risk factors. (2009) (73)
Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data. (1997) (73)
Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. (2013) (72)
Cardiovascular risk factors and non-invasive assessment of subclinical atherosclerosis in youth. (2010) (72)
Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention (2015) (72)
Common Carotid Intima-Media Thickness Measurements Do Not Improve Cardiovascular Risk Prediction in Individuals With Elevated Blood Pressure: The USE-IMT Collaboration (2014) (71)
Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). (2011) (70)
Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease (2012) (70)
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. (2019) (65)
Resting heart rate: a modifiable prognostic indicator of cardiovascular risk and outcomes? (2008) (65)
The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences (2005) (64)
Prevalence and predictors of subclinical atherosclerosis among asymptomatic "low risk" individuals in a multiethnic population. (2008) (63)
The relationship between dysglycemia and atherosclerosis in South Asian, Chinese, and European individuals in Canada: a randomly sampled cross-sectional study. (2003) (62)
Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. (2004) (62)
Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). (2009) (61)
Prevalence of mitral valve prolapse in ethnic groups. (2004) (59)
Common carotid intima-media thickness does not add to Framingham risk score in individuals with diabetes mellitus: the USE-IMT initiative (2013) (59)
Common Carotid Intima-Media Thickness Relates to Cardiovascular Events in Adults Aged <45 Years (2015) (58)
Randomized clinical trial of homocysteine level lowering therapy and fractures. (2007) (53)
Measures of cardiovascular risk and subclinical atherosclerosis in a cohort of women with a remote history of preeclampsia. (2013) (52)
Lipid lowering for primary prevention (2009) (52)
Automated oscillometric blood pressure versus auscultatory blood pressure as a predictor of carotid intima–medial thickness in male firefighters (2007) (52)
Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study (2019) (51)
The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators. (1998) (51)
Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients (2003) (50)
Effect of long-term therapy with ramipril in high-risk women. (2002) (49)
The new dyslipidemia guidelines: what is the debate? (2015) (49)
Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial. (2006) (47)
The differential association between various anthropometric indices of obesity and subclinical atherosclerosis. (2009) (46)
Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events (2013) (45)
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]). (2009) (45)
Impact of Cigarette Smoking in High-Risk Patients Participating in a Clinical Trial. A Substudy from the Heart Outcomes Prevention Evaluation (HOPE) Trial (2005) (45)
Drug treatment in heart failure (2000) (43)
Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial). (2005) (42)
Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE. (1996) (42)
Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis (2021) (42)
Venous thromboembolism in association with features of the metabolic syndrome. (2007) (40)
The Prognostic Significance of Bundle Branch Block in High‐Risk Chronic Stable Vascular Disease Patients: A Report from the HOPE Trial (2009) (39)
Lipoprotein‐Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease (2016) (38)
Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies (2015) (38)
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial (2014) (38)
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. (2019) (37)
Risk of premature stroke in recent immigrants (PRESARIO) (2010) (37)
Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART) (2008) (37)
Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. (2007) (36)
Relationship between brachial artery flow-mediated dilatation, hyperemic shear stress, and the metabolic syndrome (2008) (36)
The fate of endothelial function testing: rationale and design of the Firefighters And Their Endothelium (FATE) study. (2003) (36)
5 flourouracil-induced apical ballooning syndrome: a case report. (2009) (36)
Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatients. (2010) (35)
The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases (2001) (35)
Homocysteine-lowering B vitamin therapy in cardiovascular prevention--wrong again? (2008) (35)
Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials. (1998) (34)
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis (2002) (34)
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) (2013) (33)
Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies (2003) (32)
Homocyst(e)ine and Cardiovascular Disease (2000) (32)
Reciprocal electrocardiographic changes in acute myocardial infarction. (1985) (31)
Are the ACC/AHA guidelines on the treatment of blood cholesterol a game changer? A perspective from the Canadian Cardiovascular Society Dyslipidemia Panel. (2014) (30)
Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study. (2005) (30)
Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. (2020) (29)
Effects of blood pressure and lipid lowering on cognition (2019) (29)
Emerging approaches in preventing cardiovascular disease (1999) (29)
Carotid artery intima-media thickness--a new noninvasive gold standard for assessing the anatomic extent of atherosclerosis and cardiovascular risk? (1999) (29)
Acquired left ventricular to right atrial communication and complete heart block following nonpenetrating cardiac trauma. (1996) (28)
Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial (2017) (27)
Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity. (2003) (27)
Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. (2016) (26)
Effects of oxygen free radicals and scavengers on the cardiac extracellular collagen matrix during ischemia-reperfusion. (1994) (26)
Polypill: the evidence and the promise (2009) (26)
Myocardial infarction associated with recency of immigration to Ontario. (2010) (24)
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism (2009) (24)
Cardiovascular Risk in Patients with Early Renal Insufficiency (2002) (23)
Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction? (2007) (23)
Homocysteine: to screen and treat or to wait and see? (2000) (23)
Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. (2017) (23)
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022) (23)
Identification and management of patients at elevated cardiometabolic risk in canadian primary care: how well are we doing? (2013) (22)
Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration. (2005) (21)
Association of Apolipoproteins B and A-1 With Markers of Vascular Health or Cardiovascular Events. (2017) (21)
Summary of randomized trials of angiotensin converting enzyme inhibitors. (1999) (21)
Incremental Value of Left Ventricular Systolic and Diastolic Function to Determine Outcome in Patients with Acute ST‐Segment Elevation Myocardial Infarction: The Echocardiographic Substudy of the OASIS‐6 Trial (2014) (20)
Modifying the natural history of atherosclerosis: the SECURE trial. (2001) (20)
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements? (2012) (18)
Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target? An Antagonist View From the HOPE-3 Trial (Heart Outcomes Evaluation-3). (2016) (18)
Do antioxidant vitamins protect against atherosclerosis? The proof is still lacking*. (2001) (17)
Hemodynamic Performance of Stentless Versus Stented Valves: A Systematic Review and Meta‐Analysis (2008) (17)
Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial (2017) (17)
Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results. (2009) (17)
The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers. (2005) (17)
The effect of iron status on vascular health (2006) (17)
Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients (2014) (16)
Effects of ACE Inhibitors on Mortality When Started in the Early Phase of Myocardial Infarction: Evidence from the Larger Randomized Controlled Trials (1995) (16)
A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care (2013) (15)
Increased cardiovascular risk after pre‐eclampsia in women with dysglycaemia (2013) (15)
Clustering of cardiovascular risk factors and carotid intima-media thickness: The USE-IMT study (2017) (15)
Low resting heart rates are associated with new‐onset atrial fibrillation in patients with vascular disease: results of the ONTARGET/TRANSCEND studies (2015) (15)
Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease. (2005) (15)
Use of carotid ultrasound to stratify risk. (2001) (15)
The SPRINT and the HOPE-3 Trial in the Context of Other Blood Pressure-Lowering Trials. (2016) (15)
Tricuspid Valve Regurgitation Following Temporary or Permanent Endocardial Lead Insertion, and the Impact of Cardiac Resynchronization Therapy (2014) (14)
Secondary prevention of ischaemic cardiac events. (2002) (14)
Dose response of ACE inhibitors: implications of the SECURE trial (2001) (14)
Vitamin E Supplementation, Cardiovascular Events, and Cancer—Reply (2005) (14)
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. (2021) (14)
Effect of Insulin Glargine and n-3 FA on Carotid Intima-Media Thickness in PeopleWithDysglycemiaatHighRiskfor Cardiovascular Events The Glucose Reduction and Atherosclerosis Continuing Evaluation Study ( ORIGIN-GRACE ) (2013) (13)
Cardiovascular risk factors and subclinical atherosclerosis among Nunavik Inuit. (2012) (13)
The Fluid Study Protocol: A Randomized Controlled Study on the Effects of Bioimpedance Analysis and Vitamin D on Left Ventricular Mass in Peritoneal Dialysis Patients (2011) (12)
Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). (2008) (12)
The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics (2009) (12)
Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE. (2005) (11)
Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study (2009) (11)
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial (2018) (11)
Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. (2018) (10)
Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions. (2006) (10)
Antiatherosclerotic Effects of ACE Inhibitors (2001) (10)
Vitamin D and progression of carotid intima‐media thickness in HIV‐positive Canadians (2018) (10)
Cardiac Function Stratification Based on Echocardiographic or Clinical Markers of Left Ventricular Filling Pressures Predicts Death and Hospitalization Better Than Stratification by Ventricular Systolic Function Alone (2007) (10)
Giant left atrial myxoma and associated mitral valve pathology. (2007) (10)
2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. (2022) (9)
Myocardial vacuolization, a marker of ischemic injury, in surveillance cardiac biopsies posttransplant: Correlations with morphologic vascular disease and endothelial dysfunction. (1996) (9)
Clinical Evidence: Emerging approaches in preventing cardiovascular disease. (1999) (9)
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants (2021) (8)
Abstract 1134: Plasma Renin Activity is Associated With Increased Cardiovascular Events and Mortality in the HOPE Study (2009) (8)
Impact of ramipril on the circadian periodicity of acute myocardial infarction. (2006) (8)
Alcohol Consumption and Common Carotid Intima-Media Thickness: The USE-IMT Study (2017) (7)
The effect of large unilamellar vesicles on vascular function in patients with coronary atherosclerosis. (2008) (7)
Position Statement Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group Cardiometabolic Risk Working Group: Executive Committee: (2011) (7)
Antiatherosclerotic effects of ACE inhibitors: where are we now? (2001) (7)
The clinical relevance of pharmacological blood pressure lowering mechanisms. (2004) (7)
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline (2020) (7)
Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study (2018) (6)
Brief Vigorous Stair Climbing Effectively Improves Cardiorespiratory Fitness in Patients With Coronary Artery Disease: A Randomized Trial (2021) (6)
Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. (2020) (6)
Multivitamins in prevention of cardiovascular disease. (2012) (6)
Lipoprotein-associated phospholipase A2: a new therapeutic target. (2010) (5)
Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. (2021) (5)
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial (2021) (5)
Effect of Ramipril and Vitamin E on Atherosclerosis (2001) (5)
A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. (2017) (5)
Secondary prevention of ischaemic cardiac events. (2002) (5)
The cost implication of primary prevention in the HOPE 3 trial. (2019) (4)
CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. (2018) (4)
Ramipril prevents major cardiovascular events in high-risk women: results of the HOPE trial (2002) (4)
Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult Primary Panel : (2016) (4)
Pneumococcal endocarditis causing valve destruction in the absence of vegetations on transesophageal echocardiography: a series of 3 consecutive cases. (2013) (4)
The role of icosapent ethyl in cardiovascular risk reduction (2021) (3)
Young Women With Acute Myocardial Infarction and the Posthospital Syndrome. (2015) (3)
Epidemiology of ischemic heart disease in women. (2001) (3)
Should patients with stable coronary artery disease be treated with ACE inhibitor therapy? (2005) (3)
Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk (2021) (3)
New Trial Data on Prevention: Potassium and CV Risk in Hope (2003) (3)
The role of vitamins in the prevention of coronary artery disease (2000) (3)
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. (2022) (2)
Effect of Controlling Hyperglycemia With Diet on QT Abnormalities in Newly Diagnosed Patients With Type 2 Diabetes (2004) (2)
Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk diabetic patients (2002) (2)
Racial and Ethnic Differences in the Association Between Classical Cardiovascular Risk Factors and Common Carotid Intima‐Media Thickness: An Individual Participant Data Meta‐Analysis (2022) (2)
Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial. (2022) (2)
(SECURE) Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E Effects of Ramipril and Vitamin E on Atherosclerosis : The Study to Evaluate (2009) (2)
[PP.26.05] BLOOD PRESSURE LOWERING IN INTERMEDIATE RISK PEOPLE WITHOUT VASCULAR DISEASE (2016) (2)
Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial (2018) (2)
P858Women with stable coronary artery disease have better clinical outcomes than men, but this association is modified by degree of depression: insights from the STABILITY trial (2017) (2)
Abstract 18856: Relationships Between ‘Mediterranean’ and ‘Western’ Dietary Patterns and Major Cardiovascular Events in Patients With Stable Coronary Heart Disease in the STABILITY Study (2014) (2)
Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk (2022) (2)
Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial. (2016) (2)
Lipoprotein-associated phospholipase A 2 : A new therapeutic target (2010) (2)
Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. (2020) (2)
In-Hospital Initiation of Sacubitril/Valsartan in Stabilised Patients with Heart Failure and Reduced Ejection Fraction Naïve to Renin-Angiotensin System Blocker: An Analysis of the Transition Study (2019) (2)
What do physicians need to know in order to 'prescribe' mobile applications to patients with cardiovascular disease? (2019) (2)
Abstract 19384: Favorable Association Between a Mediterranean Dietary Pattern and Cardiovascular Risk Factors in Patients with Stable Coronary Heart Disease in the STABILITY Study (2014) (2)
Initiation of Sacubitril/Valsartan in Patients with De Novo Heart Failure with Reduced Ejection Fraction: An Analysis of the Transition Study (2019) (2)
Emerging approaches in the prevention of atherosclerotic cardiovascular diseases. (1998) (2)
Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm (2019) (2)
Surrogates of surrogates: the story of hypertension and 24 h blood pressure monitoring. (2005) (2)
Rationale , Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s ( COMPASS ) Trial (2017) (2)
Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke (2021) (1)
Abstract P171: The “Hub and Spoke” Model of Heart Function Care Achieves Quality Index Markers (2018) (1)
1.10: A pilot study evaluating the predictive value of noninvasive pharmacological cardiovascular stress testing before orthopaedic surgery (2007) (1)
Quality of Life and its Determinants in Heart Failure Patients at a Major Tertiary Academic Center in Ontario, Canada (2020) (1)
Losartan compared with captopril reduced mortality but not renal function in heart failure (1997) (1)
High dose lisinopril was more effective than low dose for reducing combined mortality and cardiovascular events in congestive heart failure (2000) (1)
The secondary prevention of cardiovascular disease (2005) (1)
Very high frequency intravascular ultrasound in vitro identification and quantitation of components of the human arterial wall (1991) (1)
Is High-intensity Stair Climbing An Effective Alternative To Traditional Cardiac Rehabilitation Exercise? (2020) (1)
Smoking, Obesity, and Disability Benefits or Litigation Are Not Associated with Clinically Important Reductions in Physical Functioning After Intramedullary Nailing of Tibial Shaft Fractures: A Retrospective Cohort Study. (2020) (1)
Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients. (2019) (1)
Neurocognitive outcomes after standard aortic versus femoral cannulation in coronary artery bypass graft surgery (2000) (1)
The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale (2020) (1)
PCV4 FIRST ANALYSIS OF CLINICAL SIGNIFICANT INTERACTIONS IN HIGH-RISK CARDIOVSCULAR PATIENTS ENROLLED INTO HOPE-TOO TRIAL IN SLOVAKIA IN THE THIRD YEAR OF TRIAL PARTICIPATION (2004) (0)
Echocardiographic Assessment of Tricuspid Valve Regurgitation Induced by Temporary or Permanent Leads in Patients Undergoing Ablation or Permanent Device Implantation (2013) (0)
Ischemic heart disease: the next target for the angiotensin-converting enzyme inhibitors (2000) (0)
Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure (2022) (0)
Comparisons of cardiac indices between Asians and non-Asians with high risk of cardiovascular disease: the ONTARGET cardiac MRI substudy (2006) (0)
247 How Do Canadian Primary Care Physicians in Family Health Teams Compare With Those in Solo-Physician Practices in Their Assessment and Management of Patients With Elevated Cardiometabolic Risk? (2012) (0)
Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. Editorial (2007) (0)
The responsibilities of the World Medical Association President (2009) (0)
Cardiovascular Protective Effects of Angiotensin Converting Enzyme Inhibitors (1996) (0)
High-dose lisinopril was more effective than low-dose for reducing combined mortality and cardiovascular events in CHF (2000) (0)
Cardiovascular responses to high‐intensity stair climbing in individuals with coronary artery disease (2022) (0)
The SECURE study: Treatment With ramipril slows atherosclerosis, Vitamin E does not (2002) (0)
Abstract 11898: Effects of Insulin Glargine on Left Ventricular Mass and Function in Patients With Dysglycemia (2014) (0)
Low vitamin E levels increased the risk for angina pectoris in men (1991) (0)
Abstract (2007) (0)
Abstract 13687: Legacy of Lipid Lowering in Preventing Fatal and Non Fatal Cardiovascular Events in Individuals Without Cardiovascular Disease During 3 Years of Post -Trial Observation in the Hope 3 (Heart Outcomes Prevention Evaluation 3) Study (2019) (0)
The cost-effectiveness of Rivaroxaban with or without aspirin in the COMPASS trial. (2022) (0)
Increasing maximal carotid artery intima–media thickness was associated with increasing risk of CV events (1999) (0)
750 Are Lifestyle Modifications Being Appropriately Recommended in the Canadian Primary Care Practice to Manage Elevated Cardiometabolic Risk (2012) (0)
Abstract 18220: Impact of Lipid and Blood Pressure Reduction on Erectile Dysfunction in Persons at Intermediate Risk for Cardiovascular Disease (2016) (0)
Abstract 12243: Associations Between Physical Activity and Prognostic Biomarkers in Patients With Stable Coronary Heart Disease in the STABILITY Trial (2015) (0)
Abstract 3498: Neither Ramipril Nor Vitamin E Reduces the Incidence of Atrial Fibrillation. Results of the HOPE Study. (2006) (0)
Edinburgh Research Explorer Race/Ethnic Differences in the Associations of the Framingham Risk Factors with Carotid IMT and Cardiovascular Events (2018) (0)
Abstract 1188: Prognostic Significance of Markers of Vascular Health: Long-term Results From the Firefighters And Their Endothelium (FATE) Study (2009) (0)
A Comparison of How Canadian Primary Care Physicians in Family Health Teams and Solo Physician Practices Manage Cardiometabolic Risk in Patients with Type 2 Diabetes Mellitus (2012) (0)
METABOLIC SYNDROME, MICROVASCULAR FUNCTION AND THEIR INFLUENCE ON THE RISK OF FUTURE CARDIOVASCULAR EVENTS: RESULTS FROM THE FIREFIGHTERS AND THEIR ENDOTHELIUM (FATE) STUDY (2016) (0)
Mitral-valve prolapse was not associated with stroke in young patients (1999) (0)
Abstract 17944: Effects of School-Based Interventions on Body Mass Index in Children and Adolescents: a Systematic Overview and Meta-analysis (2014) (0)
248 Underestimation of Cardiovascular Risk in Patients With Elevated Cardiometabolic Risk in the Canadian Primary Care Setting (2012) (0)
Angiotensin Antagonism Effect of Long-Term Therapy With Ramipril in High-Risk Women (2016) (0)
59 BNP predicts echocardiographic severity of diastolic dysfunction in heart failure (2007) (0)
Poster session Thursday 12 December - PM: 12/12/2013, 14:00-18:00 * Location: Poster area (2013) (0)
Response to Letter by Obeid and Herrmann (2009) (0)
Brachial Flow-Mediated Dilation and Atherosclerosis elationship Between Carotid Artery ntima-Media Thickness and Brachial Artery low-Mediated Dilation in Middle-Aged Healthy Men (2016) (0)
Abstract 2420: Effect of Rosiglitazone on Left Ventricular Systolic and Diastolic Function and on NT-proBNP: Results of the Echocardiographic and Biomarker Substudy of the DREAM Trial (2008) (0)
Abstract 104: First Stroke Reduced 44 Percent by Well Tolerated Medications. Stroke Outcomes From the Heart Outcomes Prevention Evaluation 3 Study (2018) (0)
Apical ballooning syndrome, emotional stress and women: reply (2006) (0)
Aggressive as opposed to moderate low-density lipoprotein cholesterol lowering strategies reduced the progression of atherosclerosis in grafts and reduced further revascularization. (1997) (0)
Management of Cardiometabolic Risk in Patients with and without Type 2 Diabetes Mellitus in Canadian Primary Care Settings (2012) (0)
Abstract 13938: Relationships Between ‘Mediterranean’ and ‘Western’ Dietary Patterns and Biomarkers Associated With Increased Cardiovascular Risk in Patients With Stable Coronary Heart Disease in the Global STABILITY Trial (2015) (0)
THE HIGH PREVALENCE OF FAMILIAL HYPERCHOLESTEROLEMIA IN A POPULATION OF ASCVD PATIENTS WITH LDL-C ABOVE TARGET: AN ANALYSIS FROM THE REACT REGISTRY (2018) (0)
Regression of left ventricular hypertrophy and its effect on cardiovascular morbidity and mortality (2003) (0)
We-W31:5 Homocysteine and folic acid levels and relation to carotid atherosclerosis in high-risk individuals (2006) (0)
Abstracts of the Fast Tracked Online Articles (2013) (0)
Enzyme Inhibitors in Cardiac and Vascular Protection (2005) (0)
Low Omega-3 Index in Erythrocytes Is a Risk Factor for Progression of Atherosclerosis in People Living With HIV (2013) (0)
LV structure in Asians and non-Asians with cardiovascular disease: Results from the ontarget cardiac MRI sub-study (2006) (0)
Gaps in Medical and Device Therapy for Patients with Left Ventricular Systolic Dysfunction: The EchoGap Study (2014) (0)
156 NT‐proBNP predicts cardiovascular outcomes in patients with heart failure and preserved ejection fraction (2007) (0)
Emerging Approaches in Cardiovascular Prevention (2007) (0)
STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone) People With Impaired Glucose Tolerance or Impaired Fasting Glucose: Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in (2011) (0)
Vitamin E may increase risk for heart failure. (2005) (0)
Vitamin E and β-carotene were not effective in men at high risk for coronary events (1998) (0)
Abstract 23084: Marked Global Variability in Cost Effectiveness of Lipid-Lowering and Combination Antihypertensive Therapies in Primary Prevention: Analyses of the HOPE-3 Trial (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Eva Marie Lonn?

Eva Marie Lonn is affiliated with the following schools:

Eva Marie Lonn's Academic­Influence.com Rankings

Eva Marie Lonn's Degrees

Why Is Eva Marie Lonn Influential?

Eva Marie Lonn's Published Works

Published Works

What Schools Are Affiliated With Eva Marie Lonn?

Eva Marie Lonn's AcademicInfluence.com Rankings